-
GenFleet Therapeutics Announces FDA's Clinical Trial Approval for GFH925 (KRAS G12C Inhibitor) Monotherapy in Phase III Registrational Study Treating Metastatic Colorectal Cancer
19 Apr 2024 12:46 GMT
… , a clinical-stage biotechnology company focusing on cutting … and Drug Administration (FDA) has granted the clinical trial approval … GFH925 in combination with cetuximab is ongoing in Europe … first- and second-line treatments are based on combination …
-
Boundless Bio doses first subject in advanced cancer treatment trial
12 Apr 2024 10:28 GMT
… gene amplifications.
The STARMAP trial is an open-label, … of BBI-825.
The trial will also establish the … specifically encorafenib and cetuximab, or adagrasib and cetuximab for colorectal cancer … Boundless Bio to enter clinical trials.
As a selective, oral …
-
Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications
11 Apr 2024 12:31 GMT
… Ph.D., Chief Medical Officer at Boundless Bio. … treatment,” said Rona Yaeger, M.D., Gastrointestinal Oncologist and Early Drug … encorafenib and cetuximab, or adagrasib and cetuximab, in patients … unfavorable results from clinical trials or preclinical studies; …
-
Bristol Myers announces positive results from phase 1/ 2 KRYSTAL─1 study of Krazati in combo with cetuximab to treat patients with previously treated KRASG12C─mutated locally advanced or metastatic CRC
10 Apr 2024 10:19 GMT
… , Department of Gastrointestinal Medical Oncology at The University … the FDA had accepted a supplemental new drug application … for Krazati in combination with cetuximab as a targeted treatment … the KRYSTAL-1 clinical trial.
This study was …
-
Human medicines European public assessment report (EPAR): Braftovi, encorafenib, Date of authorisation: 19/09/2018, Revision: 13, Status: Authorised
09 Apr 2024 11:34 GMT
The most common side effects with Braftovi and binimetinib taken together at the highest recommended doses are tiredness, nausea (feeling sick) and vomiting, abdominal pain, diarrhoea, retinal detachment (an eye problem that leads to poor vision), joint …
-
AACR: Combination treatment is well-tolerated, shows antitumor effects in KRAS G12C-mutated metastatic colorectal cancer
08 Apr 2024 17:11 GMT
… the anti-EGFR antibody cetuximab demonstrated promising anti- … D., professor of Gastrointestinal Medical Oncology and associate vice … trial. The FDA granted accelerated approval to adagrasib for the treatment … and that Phase III trials are currently ongoing.
The …
-
KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
08 Apr 2024 15:42 GMT
… drug application for KRAZATI in combination with cetuximab as a targeted treatment … KRYSTAL-1 clinical trial.
This study was … frontiers in personalized medicine and, through innovative … development and commercialization of pharmaceutical products. All statements …
-
Cancer Drugs (Antibody Drug Conjugates): An FDA Perspective
04 Apr 2024 21:45 GMT
… Pharmacology Considerations for Antibody-Drug Conjugates. FDA’s Guidance specifically outlines … new treatment modalities. Foley’s team of FDA regulatory and clinical trial …
multiple myeloma
2020
Cetuximab saratolacan
Akalux
Rakuten Medical
Head and neck …
-
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation
02 Apr 2024 20:15 GMT
… biotechnology company pioneering physics-based approaches to expand treatment … Louis Kayitalire, MD, Chief Medical Officer at Nanobiotix. “We … with or without cetuximab, for the treatment of patients with … of NBTXR3 with Janssen Pharmaceutica NV, a Johnson …
-
One Good, One Bad News For Bristol Myers Squibb's Marketed Drugs: Details
01 Apr 2024 13:57 GMT
… trials.
The company will complete a full evaluation of the YELLOWSTONE trial … FDA granted accelerated approval for Krazati as a targeted treatment … In 2023, the Medicines and Healthcare Products … drug application for Krazati in combination with cetuximab …